What is ANI Pharmaceuticals's revenue?

ANI Pharmaceuticals (ANIP) generated $923.7M in revenue over the trailing twelve months, up 37.0% year over year.

Is ANI Pharmaceuticals profitable?

ANI Pharmaceuticals reported $92.1M in net income over the trailing twelve months, a 10.0% net margin.

What are ANI Pharmaceuticals's profit margins?

Gross margin is 60.8% and operating margin is 13.4%, with a 10.0% net margin.

What is ANI Pharmaceuticals's earnings per share?

ANI Pharmaceuticals's diluted EPS over the trailing twelve months is $3.94.

Where does ANI Pharmaceuticals's income statement data come from?

Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

ANI Pharmaceuticals ANIP Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$923.71M+4.6%	$883.37M+6.8%	$826.88M+10.6%	$747.4M+10.9%	$674.07M+9.7%
Total cost of revenue	$361.86M+6.0%	$341.31M+6.2%	$321.32M+10.4%	$291.01M+6.2%	$274.09M+9.5%
Gross profit	$561.85M+3.7%	$542.06M+7.2%	$505.56M+10.8%	$456.39M+14.1%	$399.98M+9.8%
Gross margin	60.8%-0.5pp	61.4%+0.2pp	61.1%+0.1pp	61.1%+1.7pp	59.3%+0.1pp
Research and development	$51.7M+0.1%	$51.66M-7.8%	$56.05M+4.0%	$53.87M+20.7%	$44.63M+0.1%
Selling, general and administrative	$314.87M-0.9%	$317.75M+4.3%	$304.67M-0.8%	$307.09M+10.4%	$278.14M+11.4%
Total costs & expenses	$799.92M+3.6%	$772.27M+2.3%	$754.93M+3.1%	$732.21M+9.7%	$667.6M+8.8%
Operating income	$123.79M+11.4%	$111.09M—	——	——	——
Operating margin	13.4%+0.8pp	12.6%—	——	——	——
Interest expense	-$18.35M+8.5%	-$20.06M+7.4%	-$21.66M-12.4%	-$19.27M-4.2%	-$18.49M-5.0%
Other income (expense), net	$1.09M-43.9%	$1.93M+758%	-$294K+85.1%	-$1.98M+48.0%	-$3.8M+5.7%
Income before income taxes	$116.03M+21.1%	$95.79M+89.5%	$50.55M+443%	-$14.75M+46.5%	-$27.56M-24.1%
Income tax expense	$23.88M+36.8%	$17.45M+74.9%	$9.98M+320%	-$4.54M+30.3%	-$6.51M-76.5%
Net income	$92.15M+17.6%	$78.34M+93.1%	$40.57M+497%	-$10.21M+51.5%	-$21.05M-13.6%
Net margin	10%+1.1pp	8.9%+4.0pp	4.9%+6.3pp	-1.4%+1.8pp	-3.1%-0.1pp
Diluted earnings per share	$3.94+17.6%	$3.35+106%	$1.63+312%	-$0.77+39.4%	-$1.27-11.4%
EBITDA	$213.23M+5.3%	$202.51M+36.9%	$147.95M+75.5%	$84.31M+25.8%	$67M+26.6%
EBITDA margin	23.1%+0.2pp	22.9%+5.0pp	17.9%+6.6pp	11.3%+1.3pp	9.9%+1.3pp
EBIT	$123.79M+11.4%	$111.09M+96.5%	$56.55M+27,028%	-$210K+97.6%	-$8.93M+39.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about ANI Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ANI Pharmaceuticals's revenue?: ANI Pharmaceuticals (ANIP) generated $923.7M in revenue over the trailing twelve months, up 37.0% year over year.
Is ANI Pharmaceuticals profitable?: ANI Pharmaceuticals reported $92.1M in net income over the trailing twelve months, a 10.0% net margin.
What are ANI Pharmaceuticals's profit margins?: Gross margin is 60.8% and operating margin is 13.4%, with a 10.0% net margin.
What is ANI Pharmaceuticals's earnings per share?: ANI Pharmaceuticals's diluted EPS over the trailing twelve months is $3.94.
Where does ANI Pharmaceuticals's income statement data come from?: Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.